ILiAD Appoints Former GSK Exec as Chief Business Officer

ILiAD Biotechnologies Inc., an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, has appointed Antony Blanc, former VP, Head of Global Marketing and Global Strategic Pricing at GSK Vaccines, as Chief Business Officer (CBO).

Antony Blanc PhD is a seasoned biopharmaceutical executive with extensive experience in corporate strategy, vaccine development and commercialization, business development and partnering.

Experience

Prior to ILiAD, Blanc served as Chief Business and Commercial Officer at CureVac as well as various global commercial leadership positions at GSK Vaccines and in McKinsey’s European biotech practice. He brings a strong track record of building and executing growth strategies across clinical-stage and commercial organizations and will oversee ILiAD’s business development, commercial and long-term value creation initiatives.

“ILiAD has built a compelling platform with BPZE1 that has the potential to redefine pertussis vaccination and deliver meaningful public health benefit,” said Blanc. “I’m excited to join the team at this pivotal moment and help guide the Company’s strategic growth as it advances toward late-stage development and beyond.”